In this episode Carmen Solorzano, MD, Chair of the SSO Endocrine Disease Site Work Group, Electron Kebebew, MD, and Geoffrey Young, MD, PhD, discuss two practice changing studies regarding the management of Medullary and Anaplastic Thyroid Cancer. Carmen Solorzano, MD, Professor of Surgery, Chair, Department of Surgery, and Director, Vanderbilt Endocrine Surgery Geoffrey Young, MD, PhD, Chief, Head and Neck Surgery; Miami Cancer Institute Electron Kebebew, MD, Professor and Chief, Stanford University School of Medicine References/Resources 1-Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. Wirth LJ et al. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651.PMID: 32846061 2- 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer- American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force. KC Bible, E Kebebew et al. Thyroid Published Online:12 March 2021https://doi.org/10.1089/thy.2020.0944 3-Nihilism no more: The 2021 ATA Anaplastic Thyroid Cancer Guidelines. JD Pasternak, TE Angell, J Lorch. Clinical Thyroidology Vol. 33, No.5. Published Online:7 May 2021https://doi.org/10.1089/ct.2021;33.229-234